Virtual reality cognitive-behavioural therapy versus cognitive-behavioural therapy for paranoid delusions: a study protocol for a single-blind multi-Centre randomised controlled superiority trial.
Cognitive Behavioural therapy
Cost-effectivity
Delusions
Paranoia
Psychotic disorder
Social anxiety
Social functioning
Virtual reality
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
11 10 2021
11 10 2021
Historique:
received:
16
07
2021
accepted:
14
09
2021
entrez:
12
10
2021
pubmed:
13
10
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Seventy per cent of patients with psychotic disorders has paranoid delusions. Paranoid delusions are associated with significant distress, hospital admission and social isolation. Cognitive-behavioural therapy for psychosis (CBTp) is the primary psychological treatment, but the median effect size is only small to medium. Virtual reality (VR) has a great potential to improve the effectiveness of CBTp. In a previous study, we found that VR based CBT (VRcbt) for paranoid delusions is superior to waiting list. As a next step, a direct comparison with CBTp is needed. The present study aims to investigate whether VRcbt is more effective and cost-effective than regular CBTp in treating paranoid delusions and improving daily life social functioning of patients with psychotic disorders. A total of 106 patients with DSM-5 diagnosis of psychotic disorder and at least moderate level of paranoid ideations will be recruited for this multicentre randomized controlled trial (RCT). Patients will be randomized to either VRcbt or standard CBTp for paranoid delusions. VRcbt consists of maximum 16 sessions in virtual social situations that trigger paranoid ideations and distress, delivered in an 8-12 week time frame. Standard CBTp also consists of maximum 16 sessions including exposure and behavioural experiments, delivered in an 8-12 week time frame. The two groups will be compared at baseline, post-treatment and six months follow-up. Primary outcome is the level of paranoid ideations in daily life social situations, measured with ecological momentary assessments (EMA) at semi-random moments ten times a day during seven days, before and after treatment. Every session, participants and therapists will rate the level of paranoid ideation and global clinical impression. Comparison of VRcbt and CBTp will provide information about the relative (cost-) effectiveness of VRcbt for this population. VRcbt may become a preferred psychological treatment for paranoid delusions and social anxiety in patients with psychotic disorder. Netherlands Trial Register, NL7758. Registered on 23 May 2019.
Sections du résumé
BACKGROUND
Seventy per cent of patients with psychotic disorders has paranoid delusions. Paranoid delusions are associated with significant distress, hospital admission and social isolation. Cognitive-behavioural therapy for psychosis (CBTp) is the primary psychological treatment, but the median effect size is only small to medium. Virtual reality (VR) has a great potential to improve the effectiveness of CBTp. In a previous study, we found that VR based CBT (VRcbt) for paranoid delusions is superior to waiting list. As a next step, a direct comparison with CBTp is needed. The present study aims to investigate whether VRcbt is more effective and cost-effective than regular CBTp in treating paranoid delusions and improving daily life social functioning of patients with psychotic disorders.
METHODS
A total of 106 patients with DSM-5 diagnosis of psychotic disorder and at least moderate level of paranoid ideations will be recruited for this multicentre randomized controlled trial (RCT). Patients will be randomized to either VRcbt or standard CBTp for paranoid delusions. VRcbt consists of maximum 16 sessions in virtual social situations that trigger paranoid ideations and distress, delivered in an 8-12 week time frame. Standard CBTp also consists of maximum 16 sessions including exposure and behavioural experiments, delivered in an 8-12 week time frame. The two groups will be compared at baseline, post-treatment and six months follow-up. Primary outcome is the level of paranoid ideations in daily life social situations, measured with ecological momentary assessments (EMA) at semi-random moments ten times a day during seven days, before and after treatment. Every session, participants and therapists will rate the level of paranoid ideation and global clinical impression.
DISCUSSION
Comparison of VRcbt and CBTp will provide information about the relative (cost-) effectiveness of VRcbt for this population. VRcbt may become a preferred psychological treatment for paranoid delusions and social anxiety in patients with psychotic disorder.
TRIAL REGISTRATION
Netherlands Trial Register, NL7758. Registered on 23 May 2019.
Identifiants
pubmed: 34635063
doi: 10.1186/s12888-021-03473-y
pii: 10.1186/s12888-021-03473-y
pmc: PMC8507393
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
496Informations de copyright
© 2021. The Author(s).
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Schizophr Bull. 2006 Oct;32 Suppl 1:S44-63
pubmed: 16916889
Schizophr Res. 2013 Mar;144(1-3):63-71
pubmed: 23332365
J Anxiety Disord. 2019 Jan;61:27-36
pubmed: 30287083
Qual Life Res. 2013 Sep;22(7):1717-27
pubmed: 23184421
Lancet. 2013 Sep 14;382(9896):951-62
pubmed: 23810019
Psychol Med. 2008 Jan;38(1):101-11
pubmed: 17903336
J Consult Clin Psychol. 1999 Dec;67(6):837-46
pubmed: 10596506
Schizophr Res. 2014 Jun;156(1):30-7
pubmed: 24731619
Psychol Med. 2018 Feb;48(3):362-391
pubmed: 28735593
Front Psychiatry. 2020 May 05;11:402
pubmed: 32431633
Am J Psychiatry. 2014 May;171(5):523-38
pubmed: 24525715
Psychol Med. 2006 Jun;36(6):749-59
pubmed: 16563204
Psychol Med. 1996 May;26(3):477-86
pubmed: 8733206
BMC Health Serv Res. 2013 Jun 15;13:217
pubmed: 23768141
Qual Life Res. 2008 Dec;17(10):1247-56
pubmed: 18855124
Psychiatry Res. 2006 Jun 30;143(1):99-108
pubmed: 16725210
Lancet Psychiatry. 2018 Mar;5(3):217-226
pubmed: 29429948
Int Clin Psychopharmacol. 2008 Mar;23(2):70-83
pubmed: 18301121
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Anxiety Disord. 2011 May;25(4):579-83
pubmed: 21353456
Behav Res Ther. 2002 Aug;40(8):961-79
pubmed: 12186358
Psychol Med. 2017 Oct;47(14):2393-2400
pubmed: 28325167
Behav Res Ther. 1992 Jan;30(1):33-7
pubmed: 1540110
J Consult Clin Psychol. 1986 Jun;54(3):381-5
pubmed: 3722567
Lancet Psychiatry. 2016 Jul;3(7):685-92
pubmed: 27371990
Aust N Z J Psychiatry. 1989 Sep;23(3):341-51
pubmed: 2803146
J Med Internet Res. 2020 May 5;22(5):e17098
pubmed: 32369036
Acta Psychiatr Scand Suppl. 2003;(416):16-23
pubmed: 12755850
J Ment Health. 2014 Aug;23(4):162-5
pubmed: 24433132
Epidemiol Psychiatr Sci. 2013 Jun;22(2):131-46
pubmed: 22831843
Behav Res Ther. 1998 Apr;36(4):455-70
pubmed: 9670605
World Psychiatry. 2018 Jun;17(2):123-132
pubmed: 29856567
J Affect Disord. 1999 Dec;56(2-3):95-101
pubmed: 10701466
Psychiatry Res. 2016 Feb 28;236:189-195
pubmed: 26795129
Schizophr Res. 2015 Oct;168(1-2):62-7
pubmed: 26255564
Schizophr Bull. 2017 Mar 1;43(2):302-315
pubmed: 28204708
Br J Psychiatry. 2012 Sep;201(3):215-20
pubmed: 22743843
Br J Psychiatry. 2016 Jul;209(1):62-7
pubmed: 27151071
Soc Psychiatry Psychiatr Epidemiol. 2014 Aug;49(8):1179-89
pubmed: 25005465
Schizophr Res. 2007 Jan;89(1-3):119-22
pubmed: 17095193
Psychol Med. 2001 Oct;31(7):1293-306
pubmed: 11681555